Literature DB >> 12394212

Use of radiologic techniques to screen for hepatocellular carcinoma.

Michael P Federle1.   

Abstract

The role of imaging in screening and evaluation of cirrhotic patients is to assess the extent of cirrhosis and portal hypertension (liver morphology, varices, ascites, vessel patency) and to detect hepatocellular carcinoma (HCC). Ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) have valuable roles, with catheter angiography usually reserved for specific problem solving. Ultrasonography is highly operator-dependent, and detection of focal masses is often difficult or impossible because of large patient body habitus and hepatic steatosis and fibrosis, which attenuate the ultrasound beam. For sonography, as well as CT and MRI, the use of intravenous contrast material with multiphasic imaging (arterial, portal venous, and delayed) is essential to accurately depict the morphology and hemodynamics of focal hepatic lesions. Computed tomography and MRI are highly accurate in diagnosis of large HCC but are much less accurate for lesions less than 2 cm in diameter. Many factors influence the choice and timing of imaging tests, including the etiology of the chronic liver disease, the elevation of serum tumor markers, and the availability and excellence of equipment and personnel. In our practice, helical multiphasic CT is obtained at least every 12 months, more frequently in patients judged to be at high risk for HCC.

Entities:  

Mesh:

Year:  2002        PMID: 12394212     DOI: 10.1097/00004836-200211002-00005

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population.

Authors:  Min Jung Park; Young-Sun Kim; Won Jae Lee; Hyo K Lim; Hyunchul Rhim; Jongmee Lee
Journal:  Eur Radiol       Date:  2010-06-19       Impact factor: 5.315

2.  The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success.

Authors:  Korosh Khalili; Ravi Menezes; Tae Kyoung Kim; Leyla Kochak Yazdi; Hyun-Jung Jang; Suraj Sharma; Jordan Feld; Morris Sherman
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

3.  Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma.

Authors:  Myeong-Jin Kim
Journal:  Gut Liver       Date:  2011-03-16       Impact factor: 4.519

4.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Authors:  Masao Omata; Laurentius A Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T P Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K Chawla; Unggul Budihusodo; Rino A Gani; C Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2010-03-18       Impact factor: 6.047

5.  Two-Phase MDCT Protocol for the Screening of Small Hepatocellular Carcinoma.

Authors:  Anita Paisant; Jérôme Boursier; Djamel Dabli; Jérôme Lebigot; Frédéric Oberti; Sophie Michalak; Valérie Vilgrain; Christophe Aubé
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.